Rasha Aboelhassan, Council Member at International Association for the Study of Lung Cancer, Senior Oncology Consultant at Nasser Institute Hospital, shared on LinkedIn:
“Yesterday, three major oncology accounts in Cairo raised some challenging questions:
- PD-L1 – positive advanced NSCLC:
What is the optimal first-line treatment? - PD – L1 testing:
How should PD-L1 be tested, reported, and interpreted? - Immunotherapy + chemotherapy:
Which patient profiles truly benefit from combination treatment rather than immunotherapy alone?
These questions may sound straightforward – but the answers are not.
PD-L1 is only one piece of the treatment decision.
What would you choose in your practice – and which patient factors drive your decision?
I invite thoracic oncologists, medical oncologists, pathologists, pulmonologists, and multidisciplinary colleagues to share their approach.
Let’s move beyond guidelines alone and discuss how we translate the evidence into real-world patient decisions.
What is your approach? What would make you choose one strategy over another?”
Rasha Aboelhassan: The Next Frontier in Small Cell Lung Cancer